Sanofi Stock Price, News & Analysis (NYSE:SNY)

$44.54 -0.11 (-0.25 %)
(As of 11/18/2017 01:47 AM ET)
Previous Close$44.54
Today's Range$44.72 - $44.40
52-Week Range$38.45 - $50.65
Volume661,417 shs
Average Volume1.52 million shs
Market Capitalization$112.54 billion
P/E Ratio14.09
Dividend Yield2.46%
Beta0.88

About Sanofi (NYSE:SNY)

Sanofi logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Sector: Pharmaceuticals - NEC
  • Symbol: NYSE:SNY
  • CUSIP: N/A
  • Web: en.sanofi.com
Debt:
  • Debt-to-Equity Ratio: 0.26%
  • Current Ratio: 1.59%
  • Quick Ratio: 1.16%
Price-To-Earnings:
  • Trailing P/E Ratio: 14.09
  • Forward P/E Ratio: 13.58
  • P/E Growth: 2.46
Sales & Book Value:
  • Annual Sales: $37.43139 billion
  • Price / Sales: 3.00
  • Cash Flow: $4.61 per share
  • Price / Cash: 9.67
  • Book Value: $25.11 per share
  • Price / Book: 1.77
Dividend:
  • Annual Dividend: $1.10
  • Dividend Yield: 2.5%
Profitability:
  • Trailing EPS: $2.13
  • Net Income: $4.8635 billion
  • Net Margins: 25.44%
  • Return on Equity: 18.89%
  • Return on Assets: 10.56%
Misc:
  • Employees: 106,859
  • Outstanding Shares: 2,521,510,000
 

Frequently Asked Questions for Sanofi (NYSE:SNY)

What is Sanofi's stock symbol?

Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi declared an annual dividend on Friday, February 17th. Stockholders of record on Monday, May 15th will be given a dividend of $1.5771 per share on Wednesday, June 7th. This represents a dividend yield of 3.65%. The ex-dividend date of this dividend is Thursday, May 11th. This is an increase from Sanofi's previous annual dividend of $1.10. View Sanofi's Dividend History.

How were Sanofi's earnings last quarter?

Sanofi (NYSE:SNY) posted its quarterly earnings data on Thursday, October, 29th. The company reported $0.89 earnings per share for the quarter, topping analysts' consensus estimates of $0.88 by $0.02. The firm earned $10.67 billion during the quarter, compared to analyst estimates of $10.97 billion. Sanofi had a net margin of 25.44% and a return on equity of 18.89%. View Sanofi's Earnings History.

When will Sanofi make its next earnings announcement?

Sanofi is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for Sanofi.

Where is Sanofi's stock going? Where will Sanofi's stock price be in 2017?

10 brokerages have issued 1-year target prices for Sanofi's shares. Their forecasts range from $52.00 to $55.00. On average, they anticipate Sanofi's stock price to reach $53.50 in the next year. View Analyst Ratings for Sanofi.

What are Wall Street analysts saying about Sanofi stock?

Here are some recent quotes from research analysts about Sanofi stock:

  • 1. According to Zacks Investment Research, "Sanofi’s Diabetes franchise is under significant pressure with key product, Lantus facing increasing competitive pressure at the payor level and the presence of biosimilar competition in several European markets and Japan. Sanofi’s outlook for its Diabetes franchise is also bleak due to a tough U.S. payer environment. At the Q2 conference call, management warned that US diabetes sales will decline faster in the second half. Other headwinds include generic competition and slower-than-expected uptake of new products like Praluent. Sanofi’s shares have underperformed the industry in the past three months. However, Sanofi's focus on streamlining its business and pursuing business development deals is encouraging. Further, new drugs like Aubagio and Lemtrada are likely to continue doing well. Estimates have remained stable ahead of Q3 earnings release. Sanofi has a positive record of earnings surprises in recent quarters." (10/6/2017)
  • 2. Argus analysts commented, "The company also has a strong new drug pipeline that includes Toujeo, a next-generation insulin product, and dipilumab, for atopic dermatitis and other inflammatory conditions," the analyst said.See also: Where Does Zika Virus Vaccine Research Stand Now? FY18 ExpectationsArgus expects the company's 2017 revenues from continuing operations to benefit from the recent acquisition of Boehringer Ingelheim's consumer health business and higher sales of multiple sclerosis products. At the same time, the firm expects reduced diabetes drug sales.The firm also sees margin pressure due to pricing pressures for diabetes products in the U.S. and costs related to the launch of Dupixent and Kevzara, partly offset by a sales force reorganization and other cost-savings initiatives."In 2018, we expect continued solid demand for multiple sclerosis drugs and increased sales in emerging markets to outweigh weaker sales of diabetes drugs, and look for the company's cost-savings program to benefit margins," (9/1/2017)

Who are some of Sanofi's key competitors?

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:

  • Serge Weinberg, Independent Chairman of the Board (Age 66)
  • Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director (Age 61)
  • Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee (Age 59)
  • Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel; Member of the Executive Committee (Age 58)
  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets; Member of the Executive Committee (Age 54)
  • Roberto Pucci, Executive Vice President, Human Resources; Member of the Executive Committee (Age 53)
  • Peter Guenter, Executive Vice President, Diabetes & Cardiovascular; Member of the Executive Committee (Age 55)
  • David Loew, Executive Vice President, Sanofi Pasteur; Member of the Executive Committee
  • Philippe Luscan, Executive Vice President, Global Industrial Affairs; Member of the Executive Committee (Age 55)
  • Alan J. Main Ph.D., Executive Vice President, Consumer Healthcare; Member of the Executive Committee (Age 63)

Who owns Sanofi stock?

Sanofi's stock is owned by a number of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.56%), Boston Partners (0.35%), Hotchkis & Wiley Capital Management LLC (0.23%), Brandes Investment Partners LP (0.13%), Wells Fargo & Company MN (0.13%) and Macquarie Group Ltd. (0.10%). View Institutional Ownership Trends for Sanofi.

Who sold Sanofi stock? Who is selling Sanofi stock?

Sanofi's stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Harbour Capital Advisors LLC, Envestnet Asset Management Inc., Ameriprise Financial Inc., Brandes Investment Partners LP, Stifel Financial Corp, Bank of Hawaii and Bruderman Asset Management LLC. View Insider Buying and Selling for Sanofi.

Who bought Sanofi stock? Who is buying Sanofi stock?

Sanofi's stock was purchased by a variety of institutional investors in the last quarter, including Boston Partners, Fisher Asset Management LLC, Renaissance Group LLC, Aperio Group LLC, Crossmark Global Holdings Inc., Heartland Advisors Inc., Morningstar Investment Services LLC and Jane Street Group LLC. View Insider Buying and Selling for Sanofi.

How do I buy Sanofi stock?

Shares of Sanofi can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sanofi's stock price today?

One share of Sanofi stock can currently be purchased for approximately $44.54.

How big of a company is Sanofi?

Sanofi has a market capitalization of $112.54 billion and generates $37.43139 billion in revenue each year. The company earns $4.8635 billion in net income (profit) each year or $2.13 on an earnings per share basis. Sanofi employs 106,859 workers across the globe.

How can I contact Sanofi?

Sanofi's mailing address is 54 rue la Boetie, PARIS, 75008, France. The company can be reached via phone at +33-1-53774000 or via email at [email protected]


MarketBeat Community Rating for Sanofi (NYSE SNY)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  245 (Vote Outperform)
Underperform Votes:  301 (Vote Underperform)
Total Votes:  546
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Sanofi (NYSE:SNY)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 6 Hold Ratings, 4 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $53.50 (20.12% upside)

Consensus Price Target History for Sanofi (NYSE:SNY)

Price Target History for Sanofi (NYSE:SNY)

Analysts' Ratings History for Sanofi (NYSE:SNY)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/15/2017Barclays PLCUpgradeUnderweight -> Equal WeightN/AView Rating Details
9/15/2017J P Morgan Chase & CoReiterated RatingNeutralLowView Rating Details
9/1/2017ArgusReiterated RatingBuy$55.00MediumView Rating Details
8/1/2017Cowen and CompanyReiterated RatingMarket Perform$46.00 -> $52.00LowView Rating Details
5/11/2017Berenberg BankDowngradeBuy -> HoldLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageHold -> HoldLowView Rating Details
2/9/2017NatixisUpgradeNeutral -> BuyN/AView Rating Details
1/10/2017Leerink SwannReiterated RatingOutperformN/AView Rating Details
1/8/2017The Goldman Sachs Group, Inc.Reiterated RatingHoldN/AView Rating Details
11/29/2016Morgan StanleyUpgradeEqual Weight -> OverweightN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralN/AView Rating Details
9/14/2016Jefferies Group LLCReiterated RatingHoldN/AView Rating Details
9/13/2016BNP ParibasUpgradeUnderperform -> NeutralN/AView Rating Details
6/28/2016Citigroup Inc.Reiterated RatingNeutralN/AView Rating Details
5/3/2016Bank of America CorporationReiterated RatingBuy$58.00N/AView Rating Details
4/12/2016Chardan CapitalReiterated RatingBuyN/AView Rating Details
2/10/2016Sanford C. BernsteinLower Price TargetMarket-Perform$52.00 -> $45.00N/AView Rating Details
12/16/2015Oddo SecuritiesDowngradeReduceN/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Sanofi (NYSE:SNY)

Earnings by Quarter for Sanofi (NYSE:SNY)

Earnings History by Quarter for Sanofi (NYSE SNY)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018        
7/31/20176/30/2017$0.74$0.74$8.71 billion$8.66 billionViewN/AView Earnings Details
4/28/20173/31/2017$0.73$0.76$8.40 billion$8.65 billionViewN/AView Earnings Details
2/8/2017Q416$0.66$0.67$9.87 billion$8.88 billionViewN/AView Earnings Details
10/29/2015Q315$0.88$0.89$10.97 billion$10.67 billionViewN/AView Earnings Details
4/30/2015Q115$0.61$0.73$9.21 billion$9.78 billionViewN/AView Earnings Details
2/5/2015Q4$0.89$0.79$11.34 billion$10.39 billionViewN/AView Earnings Details
7/31/2014Q2$0.79$0.72$11.19 billion$10.82 billionViewN/AView Earnings Details
4/29/2014Q114$0.84$0.81$11.19 billion$10.88 billionViewN/AView Earnings Details
2/6/2014Q4$0.88$0.93ViewN/AView Earnings Details
10/30/2013$1.01$0.93ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sanofi (NYSE:SNY)
2017 EPS Consensus Estimate: $3.14
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.75$0.78$0.77
Q2 20171$0.74$0.74$0.74
Q3 20171$0.95$0.95$0.95
Q4 20171$0.68$0.68$0.68
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Sanofi (NYSE:SNY)

Most Recent Dividend:6/7/2017
Annual Dividend:$1.10
Dividend Yield:2.47%
Dividend Growth:-2.50% (3 Year Average)
Payout Ratio:51.64% (Trailing 12 Months of Earnings)
33.54% (Based on This Year's Estimates)
32.35% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Sanofi (NYSE:SNY)

Dividend History by Quarter for Sanofi (NYSE SNY)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/17/2017annual$1.583.65%5/11/20175/15/20176/7/2017
2/22/2016Annual$1.105/5/20165/9/20166/1/2016
2/26/2015special$1.623.91%5/6/20155/8/20156/2/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Sanofi (NYSE SNY)

Insider Ownership Percentage: 1.00%
Institutional Ownership Percentage: 9.36%
Insider Trades by Quarter for Sanofi (NYSE:SNY)
Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Insider Trades by Quarter for Sanofi (NYSE SNY)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2017SanofiMajor ShareholderBuy105,820$482.04$51,009,472.80View SEC Filing  
8/23/2017SanofiMajor ShareholderBuy60,595$478.98$29,023,793.10View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy195,000$308.27$60,112,650.00View SEC Filing  
7/8/2014SanofiMajor ShareholderBuy153,000$311.67$47,685,510.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Sanofi (NYSE SNY)

Source:
DateHeadline
Drooping Earnings Growth Downgrades Sanofi (SNY) to Hold - Investorplace.comDrooping Earnings Growth Downgrades Sanofi (SNY) to Hold - Investorplace.com
www.investorplace.com - November 18 at 12:29 AM
Drooping Earnings Growth Downgrades Sanofi (SNY) to HoldDrooping Earnings Growth Downgrades Sanofi (SNY) to Hold
investorplace.com - November 17 at 2:42 PM
Termeer protege scores $27M for Genzyme rare disease spinoffTermeer protege scores $27M for Genzyme rare disease spinoff
www.bizjournals.com - November 17 at 1:13 PM
How Did Sanofi Pasteur Perform in 3Q17?How Did Sanofi Pasteur Perform in 3Q17?
finance.yahoo.com - November 16 at 6:32 PM
Behind Sanofi’s Generics and Consumer Healthcare Business in 3Q17Behind Sanofi’s Generics and Consumer Healthcare Business in 3Q17
finance.yahoo.com - November 16 at 8:35 AM
Behind Sanofi’s Established Product Performance in 3Q17Behind Sanofi’s Established Product Performance in 3Q17
finance.yahoo.com - November 15 at 3:38 PM
Sanofi reported weak Q3 2017 results. - Seeking AlphaSanofi reported weak Q3 2017 results. - Seeking Alpha
seekingalpha.com - November 15 at 10:24 AM
Checking in with Sanofi’s Diabetes and Cardiovascular Business in 3Q17Checking in with Sanofi’s Diabetes and Cardiovascular Business in 3Q17
finance.yahoo.com - November 15 at 10:24 AM
Sanofi (SNY) Upgraded to Equal Weight by Barclays PLCSanofi (SNY) Upgraded to Equal Weight by Barclays PLC
www.americanbankingnews.com - November 15 at 8:32 AM
Zacks: Analysts Anticipate Sanofi (SNY) Will Post Quarterly Sales of $10.38 BillionZacks: Analysts Anticipate Sanofi (SNY) Will Post Quarterly Sales of $10.38 Billion
www.americanbankingnews.com - November 14 at 3:56 AM
Sanofi (SNY) Expected to Announce Earnings of $0.69 Per ShareSanofi (SNY) Expected to Announce Earnings of $0.69 Per Share
www.americanbankingnews.com - November 12 at 10:06 PM
Sanofi (SNY) Shares a Buy on Earnings Momentum - Investorplace.comSanofi (SNY) Shares a Buy on Earnings Momentum - Investorplace.com
investorplace.com - November 11 at 1:52 PM
Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA NodPharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod
finance.yahoo.com - November 10 at 11:24 AM
Sanofi (SNY) Shares a Buy on Earnings MomentumSanofi (SNY) Shares a Buy on Earnings Momentum
investorplace.com - November 10 at 10:46 AM
Applying Mathematics To Analyse Financial Markets - Part 3, Results And Examples For Sanofi And TotalApplying Mathematics To Analyse Financial Markets - Part 3, Results And Examples For Sanofi And Total
seekingalpha.com - November 7 at 10:32 AM
Sanofi (SNY) Q3 Earnings In Line, Sales Lag, Diabetes WeakSanofi (SNY) Q3 Earnings In Line, Sales Lag, Diabetes Weak
finance.yahoo.com - November 4 at 4:25 PM
Eroding Analytics Drop Sanofi (SNY) to BuyEroding Analytics Drop Sanofi (SNY) to Buy
investorplace.com - November 3 at 10:41 AM
Earnings Reaction History: Sanofi-Aventis, 33.3% Follow-Through Indicator, 1.7% Sensitive - NasdaqEarnings Reaction History: Sanofi-Aventis, 33.3% Follow-Through Indicator, 1.7% Sensitive - Nasdaq
www.nasdaq.com - November 2 at 9:01 AM
[$$] Diabetes Division Weighs on Sanofis 3Q Profits[$$] Diabetes Division Weighs on Sanofi's 3Q Profits
finance.yahoo.com - November 2 at 9:01 AM
Sanofi refines expectations on drop in sales at diabetes armSanofi refines expectations on drop in sales at diabetes arm
finance.yahoo.com - November 2 at 9:01 AM
Sanofi meets 3Q profit forecastsSanofi meets 3Q profit forecasts
finance.yahoo.com - November 2 at 9:01 AM
Sanofi, Shell and Credit Suisse - Earnings Round-UpSanofi, Shell and Credit Suisse - Earnings Round-Up
finance.yahoo.com - November 2 at 9:01 AM
Sanofi takes gloomy view of diabetes drug salesSanofi takes gloomy view of diabetes drug sales
finance.yahoo.com - November 2 at 9:01 AM
Sanofi Falls After Third-Quarter Sales Narrowly Miss ForecastsSanofi Falls After Third-Quarter Sales Narrowly Miss Forecasts
finance.yahoo.com - November 2 at 9:01 AM
Sanofi to Host Earnings CallSanofi to Host Earnings Call
finance.yahoo.com - November 2 at 9:01 AM
Sanofi: Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance ConfirmedSanofi: Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed
finance.yahoo.com - November 2 at 9:01 AM
Sanofi : Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance ConfirmedSanofi : Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed
feeds.benzinga.com - November 2 at 3:32 AM
Zealand reports royalty revenue for the third quarter of 2017Zealand reports royalty revenue for the third quarter of 2017
feeds.benzinga.com - November 2 at 3:31 AM
Sanofi (SNY) Says Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in ... - StreetInsider.comSanofi (SNY) Says Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in ... - StreetInsider.com
www.streetinsider.com - October 31 at 9:46 AM
[$$] Impact Biomedicines Gets $90 Million to Tackle Blood Cancer[$$] Impact Biomedicines Gets $90 Million to Tackle Blood Cancer
finance.yahoo.com - October 28 at 6:34 AM
High-Level Measures for Earnings Momentum Make Sanofi (SNY) a Strong BuyHigh-Level Measures for Earnings Momentum Make Sanofi (SNY) a Strong Buy
investorplace.com - October 27 at 10:39 AM
Sanofi (SNY) to Release Earnings on ThursdaySanofi (SNY) to Release Earnings on Thursday
www.americanbankingnews.com - October 26 at 5:00 AM
Leerink Swann Weighs in on Sanofis Q3 2017 Earnings (SNY)Leerink Swann Weighs in on Sanofi's Q3 2017 Earnings (SNY)
www.americanbankingnews.com - October 25 at 7:34 AM
 Analysts Anticipate Sanofi (SNY) Will Post Quarterly Sales of $10.91 Billion Analysts Anticipate Sanofi (SNY) Will Post Quarterly Sales of $10.91 Billion
www.americanbankingnews.com - October 25 at 1:58 AM
FY2017 Earnings Forecast for Sanofi Issued By Leerink Swann (SNY)FY2017 Earnings Forecast for Sanofi Issued By Leerink Swann (SNY)
www.americanbankingnews.com - October 24 at 8:29 AM
Financial Comparison: Sanofi (SNY) & Its RivalsFinancial Comparison: Sanofi (SNY) & Its Rivals
www.americanbankingnews.com - October 22 at 6:22 AM
Reviewing Sanofi (SNY) and The CompetitionReviewing Sanofi (SNY) and The Competition
www.americanbankingnews.com - October 20 at 12:22 PM
Sanofi (SNY) a Strong Buy on Outstanding Quant ScoreSanofi (SNY) a Strong Buy on Outstanding Quant Score
investorplace.com - October 20 at 10:47 AM
Stock Performance Review on Drug Makers Industry -- Pfizer, Sanofi, Heron Therapeutics, and Aerie Pharma - PR Newswire (press release)Stock Performance Review on Drug Makers Industry -- Pfizer, Sanofi, Heron Therapeutics, and Aerie Pharma - PR Newswire (press release)
www.prnewswire.com - October 20 at 8:18 AM
A scientific breakthrough offers hope for an AIDS vaccineA scientific breakthrough offers hope for an AIDS vaccine
www.cnbc.com - October 19 at 9:55 AM
Sanofi/Regenerons Dupixent Succeeds in Phase II StudySanofi/Regeneron's Dupixent Succeeds in Phase II Study
www.msn.com - October 18 at 8:45 AM
Sanofi (SNY), Regeneron (REGN) Phase 2 Study Results for Dupilumab Shows Significant Improvement Versus PlaceboSanofi (SNY), Regeneron (REGN) Phase 2 Study Results for Dupilumab Shows Significant Improvement Versus Placebo
www.streetinsider.com - October 18 at 8:45 AM
Sanofi’s Consumer Healthcare Expected to Be Long-Term DriverSanofi’s Consumer Healthcare Expected to Be Long-Term Driver
finance.yahoo.com - October 18 at 8:45 AM
Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic EsophagitisSanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
globenewswire.com - October 17 at 7:26 AM
Regeneron Pharma, Sanofi Announce Positive Phase 2 Study Results For DupilumabRegeneron Pharma, Sanofi Announce Positive Phase 2 Study Results For Dupilumab
www.rttnews.com - October 17 at 7:26 AM
Sanofi: Upward Trajectory In 2017Sanofi: Upward Trajectory In 2017
seekingalpha.com - October 17 at 7:26 AM
Dupixent May Be Strong Growth Driver for Sanofi in the FutureDupixent May Be Strong Growth Driver for Sanofi in the Future
finance.yahoo.com - October 17 at 7:26 AM
Regeneron Advances Science To Attack Arthritis, Eye Disease, MoreRegeneron Advances Science To Attack Arthritis, Eye Disease, More
finance.yahoo.com - October 17 at 7:26 AM
Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic EsophagitisRegeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
finance.yahoo.com - October 17 at 7:26 AM
Regeneron-Sanofi throat infection drug succeeds key studyRegeneron-Sanofi throat infection drug succeeds key study
finance.yahoo.com - October 17 at 7:26 AM

Social Media

Financials

Financials are not available for this stock.

Chart

Sanofi (NYSE SNY) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.